FR2918892B1 - Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations - Google Patents

Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations

Info

Publication number
FR2918892B1
FR2918892B1 FR0756515A FR0756515A FR2918892B1 FR 2918892 B1 FR2918892 B1 FR 2918892B1 FR 0756515 A FR0756515 A FR 0756515A FR 0756515 A FR0756515 A FR 0756515A FR 2918892 B1 FR2918892 B1 FR 2918892B1
Authority
FR
France
Prior art keywords
corticides
dermatological composition
inflammatory dermatological
hyaluronate fragments
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0756515A
Other languages
English (en)
Other versions
FR2918892A1 (fr
Inventor
Christine Chaumont
Jean Hilaire Saurat
Gurkan Kaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Priority to FR0756515A priority Critical patent/FR2918892B1/fr
Priority to US12/669,336 priority patent/US20100197632A1/en
Priority to PCT/EP2008/059021 priority patent/WO2009010448A2/fr
Priority to EP08774984A priority patent/EP2178538A2/fr
Priority to JP2010516471A priority patent/JP2010533673A/ja
Publication of FR2918892A1 publication Critical patent/FR2918892A1/fr
Application granted granted Critical
Publication of FR2918892B1 publication Critical patent/FR2918892B1/fr
Priority to US13/603,146 priority patent/US20130059814A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition dermatologique anti-inflammatoire destinée à une administration topique, caractérisée en ce qu'elle comprend 0,005 à 0,1 %, de préférence 0,01 à 0,05 % en poids d'un corticoïde et 0,1 à 1%, de préférence 0,5 à 1 % en poids de fragments de hyaluronate de poids moléculaire moyen compris entre 20 et 500 kDa, de préférence entre 20 et 375 kDa, plus préférentiellement entre 20 et 150 kDa.
FR0756515A 2007-07-16 2007-07-16 Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations Expired - Fee Related FR2918892B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0756515A FR2918892B1 (fr) 2007-07-16 2007-07-16 Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations
US12/669,336 US20100197632A1 (en) 2007-07-16 2008-07-10 Anti-inflammatory dermatological composition comprising corticosteroids and hyaluronate fragments, and uses thereof
PCT/EP2008/059021 WO2009010448A2 (fr) 2007-07-16 2008-07-10 Composition dermatologique anti-inflammatoire comprenant des corticoïdes et des fragments de hyaluronate, et ses utilisations
EP08774984A EP2178538A2 (fr) 2007-07-16 2008-07-10 Composition dermatologique anti-inflammatoire comprenant des corticoïdes et des fragments de hyaluronate, et ses utilisations
JP2010516471A JP2010533673A (ja) 2007-07-16 2008-07-10 コルチコステロイドとヒアルロン酸断片を含んでなる抗炎症性の皮膚用組成物、およびその使用
US13/603,146 US20130059814A1 (en) 2007-07-16 2012-09-04 Anti-inflammatory dermatological composition comprising corticosteroids and hyaluronate fragments, and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0756515A FR2918892B1 (fr) 2007-07-16 2007-07-16 Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations

Publications (2)

Publication Number Publication Date
FR2918892A1 FR2918892A1 (fr) 2009-01-23
FR2918892B1 true FR2918892B1 (fr) 2010-02-12

Family

ID=39015928

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0756515A Expired - Fee Related FR2918892B1 (fr) 2007-07-16 2007-07-16 Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations

Country Status (5)

Country Link
US (2) US20100197632A1 (fr)
EP (1) EP2178538A2 (fr)
JP (1) JP2010533673A (fr)
FR (1) FR2918892B1 (fr)
WO (1) WO2009010448A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120205645A1 (en) 2009-10-28 2012-08-16 Basf Se Heteroleptic carbene complexes and the use thereof in organic electronics
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
FR3105922B1 (fr) 2020-01-08 2022-12-02 Le Rouge Francais Composition cosmétique pour le traitement des lèvres sous forme de solide compact contenant au moins un agent probiotique et au moins un composé choisi parmi l'acide hyaluronique et ses dérivés.
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61151122A (ja) * 1984-12-25 1986-07-09 Sekisui Chem Co Ltd 外用貼付剤
JP2945993B2 (ja) * 1989-12-05 1999-09-06 武田薬品工業株式会社 外用剤
CA2208916A1 (fr) * 1997-07-03 1999-01-03 Hyal Pharmaceutical Corporation Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels
IT1309588B1 (it) * 1999-03-05 2002-01-24 Altergon Sa Cerotto con spessore sottile contenente betametasone ed acidoialuronico per il trattamento di psoriasi, dermatite, dermatosi.
JP4451070B2 (ja) * 2003-02-03 2010-04-14 生化学工業株式会社 Cd44切断誘導剤
FR2865651B1 (fr) * 2004-01-29 2007-09-28 Fabre Pierre Dermo Cosmetique Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
JP4022659B2 (ja) * 2005-05-24 2007-12-19 株式会社 糖質科学研究所 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤

Also Published As

Publication number Publication date
US20130059814A1 (en) 2013-03-07
WO2009010448A3 (fr) 2009-06-04
FR2918892A1 (fr) 2009-01-23
US20100197632A1 (en) 2010-08-05
JP2010533673A (ja) 2010-10-28
EP2178538A2 (fr) 2010-04-28
WO2009010448A2 (fr) 2009-01-22

Similar Documents

Publication Publication Date Title
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
NZ601248A (en) Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
DE602006018275D1 (de) Entzündungshemmende und/oder analgetische zusammensetzung für den darm mit verzweigten maltodextrinen
BR112012012210B8 (pt) conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
MX2010005516A (es) Composiciones que comprenden al menos un derivado del acido naftoico, de peroxido de benzoilo y al menos un agente filmogeno.
BRPI0516082A (pt) poligalactomananos catiÈnicos de alto ds para produtos de cuidado com a pele
MX2009010889A (es) Composiciones de oligo-guluronato y galacturonato.
MX2008002012A (es) Emulsion de tipo aceite en agua para la aplicacion topica en dermatologia.
EA200701029A1 (ru) Новая композиция для облегчения человеческих родов
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
PL1940381T3 (pl) Farmaceutyczne kompozycje do oczu oparte na aminokwasach i hialuronianie sodu
MX343358B (es) Tabletas de acetato de ulipristal.
TN2014000236A1 (en) Use of chemically modified heparin derivates in sickle cell disease
MX2010005210A (es) Formulacion de aceite de oliva para alivio del dolor.
MX2010004613A (es) Composicion topica.
AU2003267581A1 (en) Drug delivery
MA33743B1 (fr) Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
FR2918892B1 (fr) Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations
DK2197417T3 (da) Farmaceutisk sammensætning, omfattende s-nitrosoglutathion og polysaccharid
WO2005014524A3 (fr) Composes d'amino thiol et compositions destines a etre utilises conjointement avec un traitement du cancer
FR2936950B1 (fr) Composition cosmetique comprenant un copolymere amphiphile zwitterionique
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff
MXPA04007584A (es) Compuestos de poliamina y composiciones para su uso en conjunto con una terapia contra el cancer.
BR112015007045A2 (pt) composição de cuidado pessoal

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150331